Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 (Engensis) gene therapy for diabetic foot ulcers with PAD
NCT02563522Phase 3Terminated
- Sponsor
- Helixmith
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of Engensis in diabetic foot ulcer (DFU), sponsored by Helixmith. Started Jun 2017; status: terminated.
02
Drugs
Engensis
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02563522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563522.